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MaOBJECTIVES This study assessed 5 frequently applied arterial 18ﬂuorodeoxyglucose (18F-FDG) uptake metrics in
healthy control subjects, those with risk factors and patients with cardiovascular disease (CVD), to derive uptake
thresholds in each subject group. Additionally, we tested the reproducibility of these measures and produced recom-
mended sample sizes for interventional drug studies.
BACKGROUND 18F-FDG positron emission tomography (PET) can identify plaque inﬂammation as a surrogate endpoint
for vascular interventional drug trials. However, an overview of 18F-FDG uptake metrics, threshold values, and repro-
ducibility in healthy compared with diseased subjects is not available.
METHODS 18F-FDG PET/CT of the carotid arteries and ascending aorta was performed in 83 subjects (61  8 years)
comprising 3 groups: 25 healthy controls, 23 patients at increased CVD risk, and 35 patients with known CVD. We
quantiﬁed 18F-FDG uptake across the whole artery, the most-diseased segment, and within all active segments over
several pre-deﬁned cutoffs. We report these data with and without background corrections. Finally, we determined
measurement reproducibility and recommended sample sizes for future drug studies based on these results.
RESULTS All 18F-FDG uptake metrics were signiﬁcantly different between healthy and diseased subjects for both the
carotids and aorta. Thresholds of physiological 18F-FDG uptake were derived from healthy controls using the 90th
percentile of their target to background ratio (TBR) value (TBRmax); whole artery TBRmax is 1.84 for the carotids and 2.68
in the aorta. These were exceeded by >52% of risk factor patients and >67% of CVD patients. Reproducibility was
excellent in all study groups (intraclass correlation coefﬁcient >0.95). Using carotid TBRmax as a primary endpoint
resulted in sample size estimates approximately 20% lower than aorta.
CONCLUSIONS We report thresholds for physiological 18F-FDG uptake in the arterial wall in healthy subjects, which are
exceeded by the majority of CVD patients. This remains true, independent of readout vessel, signal quantiﬁcation
method, or the use of background correction. We also conﬁrm the high reproducibility of 18F-FDG PET measures of
inﬂammation. Nevertheless, because of overlap between subject categories and the relatively small population studied,
these data have limited generalizability until substantiated in larger, prospective event-driven studies. (Vascular
Inﬂammation in Patients at Risk for Atherosclerotic Disease; NTR5006) (J Am Coll Cardiol Img 2016;9:1198–207) © 2016
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AB BR E V I A T I O N S
AND ACRONYM S
%active slices = percentage of
active slices
CT = computed tomography
CVD = cardiovascular disease
18F-FDG =
18
ﬂuorodeoxyglucose
ICC = intraclass coefﬁcient
correlation
PET = positron emission
tomography
ROI = region of interest
SUV = standardized uptake
value
SUVmax = maximum
standardized uptake value
TBR = target to background
ratio
TBRactive slices = percentage
having at least 1 active slice
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1199A therosclerosis is a chronic, low-grade inﬂam-matory disease of the arterial wall that causesmyocardial infarction and stroke (1). Despite
aggressive primary and secondary prevention strate-
gies, long-term disability and death from cardiovas-
cular disease (CVD) continue to increase (2). Arterial
inﬂammation is strongly related to the risk of athero-
sclerotic plaque rupture. Quantiﬁcation of inﬂamma-
tion may improve patient risk stratiﬁcation and
allow new drug therapies to be tested (1).
Noninvasive imaging, in particular with 18F-ﬂuo-
rdeoxyglucose (18F-FDG) positron emission tomogra-
phy (PET), has been used in this way (3,4). Arterial
wall 18F-FDG uptake mirrors inﬂammatory activity in
atherosclerosis (5–7); inﬂammatory cells consume
large amounts of glucose in comparison with other
plaque cells. This results in 18F-FDG accumulation. In
addition, arterial 18F-FDG uptake is higher in
morphologically unstable plaques and predicts future
vascular events (8–13).SEE PAGE 1208 TBRmax = 90th percentile of
target to background ratio18F-FDG PET can assess the efﬁcacy (or futility) of
treatments designed to lower plaque inﬂammation
(14–27). As shown in Online Table 1, the number of
vascular intervention trials using 18F-FDG PET as a
surrogate marker of inﬂammation is growing, with
one-half being published in the past 2 years. Several of
these studies enriched their study populations by
excluding subjects with 18F-FDG uptake below pre-
deﬁned thresholds. However, a consensus regarding
the most appropriate thresholds is lacking (28–31),
primarily because healthy subjects, presumably
without pathological arterial inﬂammation, have not
been systematically imaged, and large-scale prospec-
tive outcome studies are awaited (32,33). Without
these data, it is challenging to enroll patients with
sufﬁcient arterial inﬂammation to need therapy and to
avoid randomizing those unlikely to respond.
In this study, we assessed 5 frequently applied
arterial 18F-FDG uptake metrics in 3 distinct groups:
healthy control subjects, those with risk factors for
CVD, and a group with established CVD. Considering
18F-FDG uptake in the arterial wall of healthy control
subjects as physiological, we determined the 90th
percentile for arterial wall inﬂammatory activity using
several commonly reported PET endpoints. Finally,
we determined the reproducibility of published mea-
sures of 18F-FDG uptake and derived optimal sample
sizes for drug studies based on our results.
METHODS
STUDY POPULATION. We recruited subjects into 3
groups: 1) healthy control subjects; 2) patients atincreased CVD risk (Framingham risk score
>10%); and 3) patients with known CVD
(experienced myocardial infarction, transient
ischemic attack, stroke, or carotid artery
atherosclerosis >12 months before PET imag-
ing). Healthy control subjects were recruited
via advertisements in newspapers and
screened to exclude those with a history of
CVD, cardiovascular risk factors, or medica-
tion use. All healthy control subjects had a
value of 0 for coronary artery calcium score.
Exclusion criteria for all subjects were age<40
years, diabetes mellitus, or inﬂammatory or
malignant disease. 18F-FDG PET/computed
tomography (CT) imaging was performed at
the AcademicMedical Center, Amsterdam, the
Netherlands. Ten subjects underwent
repeated imaging after 3 weeks to assess
interscan reproducibility. All subjects pro-
vided written informed consent. The study
was approved by the local institutional review
board and conducted according to the princi-
ples of the International Conference on
Harmonization–Good Clinical Practice.
BIOMETRIC AND BIOCHEMICAL MEASUREMENTS.
Presence of cardiovascular risk factors and use of
medication were assessed by questionnaire. EDTA
plasma was obtained to measure total cholesterol,
high-density lipoprotein cholesterol, triglycerides,
C-reactive protein, glucose, creatinine, and leukocyte
and monocyte counts using commercially available
enzymatic methods. Low-density lipoprotein choles-
terol levels were calculated using the Friedewald
equation.
18F-FDG PET/CT IMAGING AND ANALYSIS. 18F-FDG
PET/CT imaging was performed on a PET/CT scanner
(Philips, Best, the Netherlands). Subjects fasted for
>6 h before infusion of 200 MBq of 18F-FDG (5.5 mCi).
PET imaging was initiated with a low-dose, non–
contrast-enhanced CT for attenuation correction and
anatomic co-registration (slice thickness 3 mm)
90 min after 18F-FDG administration. Additionally, CT
scans were used for coronary artery calcium scoring
(Online Appendix). Images were analyzed using
OsiriX software (Geneva, Switzerland).
Figure 1 provides an overview of the 18F-FDG up-
take analysis and metrics. 18F-FDG uptake was
assessed in: 1) the carotids starting from 1 slice caudal
to the carotid bifurcation downwards; and 2) in the
aorta from 1 slice cranial to the pulmonary arteries
upwards, per standard methods (34). From each re-
gion of interest (ROI), standardized uptake values
(SUVs) were read. SUV represents 18F-FDG activity
FIGURE 1 Arterial PET/CT Images and Analysis Methods
(A) Representative CT and 18F-FDG PET/CT images of the carotid arteries (white arrow, yellow ROIs) and jugular veins (green ROIs) in a patient
with cardiovascular disease. Red scale bars indicate 2 cm. Schematics showing (B) standardized uptake values (SUVs) in the whole artery and
the background, (C) background corrections, and (D) active segment analysis with corresponding imaging parameters. A similar analysis is
performed for the aortic segment. CT ¼ computed tomography; 18F-FDG ¼ 18ﬂuorodeoxyglucose; MDS ¼ most diseased segment;
PET ¼ positron emission tomography; ROI ¼ regions of interest; SUVmax ¼ maximum standardized uptake value; SUVmean ¼ mean standardized
uptake value; TBR ¼ target to background ratio.
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1200adjusted for 18F-FDG dose, corrected for decay, and
divided by body weight. To correct for background
18F-FDG, whole artery SUV was either subtracted or
divided (target to background ratio [TBR]) by back-
ground SUV obtained from venous or remote arterial
blood. After whole artery metrics, the most-diseased
segment TBR was recorded as the mean of 3 adja-
cent slices with the highest arterial maximum stan-
dardized uptake value (SUVmax). In the active
segment analysis, slices with 90th percentile of their
TBR (TBRmax) values above a pre-deﬁned cutoff level
(either $1.60, $1.80, or $2.00 for the carotid
arteries; $2.40, $2.60, or $2.80 for the aorta) were
considered active, whereas noninﬂamed segments
were excluded. Using this approach, the percentage
of those having at least 1 active slice (TBRactive slices),the TBRactive slices and the percentage of active slices
(%active slices) were assessed.
STATISTICAL ANALYSIS. Continuous variables are
expressed as mean  SD or median and interquartile
range, unless otherwise speciﬁed. Differences in
18F-FDG uptake between the different groups were
assessed using a multivariate model to account
for age, sex, hypertension (systolic blood pressure
>140 mm Hg, diastolic blood pressure >90 mm Hg,
or use of antihypertensive medication), body mass
index, smoking, drug use (statins, ezetimibe,
angiotensin-converting enzyme inhibitors, acetylsa-
licylic acid, beta-blockers), lipid proﬁle, and glucose.
We estimated SUV and TBR upper threshold values
based on the tolerance interval (35) using the 95th
TABLE 1 Clinical Characteristics of Study Subjects
Healthy Control
Subjects (n ¼ 25)
Patients at Increased
CVD Risk (n ¼ 23)
Patients With
Known CVD (n ¼ 35) p Value* p Value†
Age, yrs 60  11 59  6 63  7 NS NS
Male 60 (15) 74 (17) 77 (27) NS NS
BMI, kg/m2 25  3 26  3 27  4 NS NS
SBP, mm Hg 134  16 135  9 133  8 NS NS
DBP, mm Hg 81  10 82  8 81  7 NS NS
Smoking 0 (0) 0 (0) 14 (5) 0.026 0.012
Lipid-lowering drugs, % yes 0 (0) 83 (19) 100 (35) <0.001 NS
Statin use 0 (0) 83 (19) 86 (30) <0.001 NS
Ezetimibe use 0 (0) 0 (0) 14 (5) <0.001 <0.001
ACE inhibitor use 0 (0) 91 (21) 100 (35) <0.001 NS
Acetylsalicylic acid use 0 (0) 70 (16) 100 (35) <0.001 NS
Beta-blocker use, % yes 0 (0) 74 (17) 100 (35) <0.001 NS
TChol, mmol/l 5.32  0.96 7.33  2.81 5.99  3.16 0.040 NS
LDL-C, mmol/l 3.24  0.97 5.42  2.63 4.18  3.11 0.011 NS
HDL-C, mmol/l 1.65  0.37 1.21  0.25 1.24  0.37 <0.001 NS
TG, mmol/l 0.89 [0.84] 1.57 [0.99] 1.42 [0.91] 0.001 NS
Glucose, mmol/l 5.04  0.33 5.40  0.75 5.41  1.19 NS NS
Creatinine, mmol/l 79 [16] 80 [17] 82 [17] NS NS
Leukocytes, 109/l 6.10  1.74 6.30  2.54 6.29  1.52 NS NS
Monocytes, 109/l 0.45  0.13 0.51  0.16 0.54  0.20 NS NS
CRP, mg/l 1.30 [1.35] 1.20 [2.00] 2.30 [3.30] NS NS
CAC scores†‡ 0 (0) 303 (110) 691 (372) <0.001 <0.001
Values are mean  SD, % (n), or median [IQR]. *p value between all groups. †p value between patients at increased CVD risk and patients with known disease. ‡Agatston score.
ACE ¼ angiotensin-converting enzyme; BMI ¼ body mass index; CAC score ¼ coronary artery calcium score; CRP ¼ C-reactive protein; DBP ¼ diastolic blood pressure;
HDL-C ¼ high-density lipoprotein cholesterol; IQR ¼ interquartile range; LDL-C ¼ low-density lipoprotein cholesterol; NS ¼ not signiﬁcant; SBP ¼ systolic blood pressure;
TChol ¼ total cholesterol; TG ¼ triglycerides.
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1201and 90th percentiles of log-normal SUV and TBR in
the healthy control subjects.
Power analyses to detect the superiority of a test
over a control in SUV and TBR were based on a 2-
sample unpaired Student t test (2-sided) and per-
formed with 80% power and an alpha of 5%. The
agreement between scans and analyses were assessed
using intraclass correlation coefﬁcients (ICC, r) and
Bland-Altman plots. The SD of the paired differences
and the coefﬁcient of variation between the initial
and repeat scans were calculated. Coefﬁcient of
variation was calculated by dividing the SD of the
paired differences by the mean value of the popula-
tion for each parameter. Values of p < 0.05 were
considered statistically signiﬁcant. Data were
analyzed using SPSS version 19.0 (SPSS Inc., Chicago,
Illinois).
RESULTS
CLINICAL CHARACTERISTICS. In total, 83 partici-
pants (61  8 years of age) were imaged, including 25
healthy control subjects, 23 patients at increased CVD
risk (median Framingham score 14% [interquartile
range: 4]), and 35 patients with a history of CVD
documented as signiﬁcant carotid artery stenosis(n ¼ 13), transient ischemic attack (n ¼ 9), stroke
(n ¼ 9), and/or myocardial infarction (n ¼ 25). Subject
demographics are listed in Table 1.
WHOLE ARTERY 18F-FDG UPTAKE. Whole artery 18F-
FDG in the carotids and aorta, expressed as SUVmax,
showed a gradual increase from healthy to diseased
subjects (Table 2). The mean difference in SUVmax
between healthy control subjects and those at
increased CVD risk was 0.30  0.08 for the carotids
and 0.36  0.09 for the aorta. The mean difference in
SUVmax between patients at increased CVD risk and
patients with known CVD was 0.10  0.08 for the
carotids and 0.28  0.10 for the aorta.
Before calculating subtraction or ratio metrics, we
demonstrated that both venous and arterial blood
18F-FDG background values were comparable be-
tween groups (Table 2, Online Table 2). In line with
this observation, 18F-FDG background corrections of
the SUV values with either subtraction or ratio (TBR)
did not affect the signiﬁcance between groups
(Table 2, Online Table 2).
ACTIVE SEGMENT APPROACH. We also examined
the TBR of the most-diseased segment TBR (Online
Table 2). In addition, an active segment analysis was
performed using several pre-deﬁned cutoffs. Using a
TABLE 2 Whole Artery and Active Segment Based 18F-FDG Uptake in Study Groups
Healthy Control
Subjects
Patients at
Increased
CVD Risk
Patients With
Known CVD p Value*
Whole artery SUVmax
Carotid arteries 1.49  0.28 1.79  0.27 1.99  0.37 <0.001
Ascending aorta 1.98  0.31 2.34  0.31 2.63  0.63 <0.001
Venous background SUVmean
Jugular veins 0.84  0.13 0.92  0.14 0.93  0.18 NS
Superior vena cava 0.96  0.11 0.84  0.16 0.90  0.20 NS
Arterial SUV–venous SUVmean
Carotid arteries 0.53  0.20 0.86  0.22 0.96  0.28 <0.001
Ascending aorta 1.14  0.22 1.49  0.23 1.73  0.54 <0.001
Whole artery TBRmax
Carotid arteries 1.55  0.23 1.94  0.27 2.13  0.30 <0.001
Ascending aorta 2.36  0.25 2.80  0.31 2.97  0.59 <0.001
Active segment approach
Carotid arteries (active $1.60) 48% of subjects 96% of patients 100% of patients
% active slices 32  40% 80  31% 90  19% 0.020
TBRactive slices 1.79  0.12 2.00  0.29 2.09  0.32 0.044
Ascending aorta (active $2.40) 88% of subjects 96% of patients 97% of patients
%active slices 74  30% 88  25% 91  18% NS
TBRactive slices 2.70  0.21 2.97  0.40 3.00  0.49 NS
*p Value for multivariate analysis adjusted for age, sex, hypertension, smoking, body mass index, drug usage,
lipid proﬁle, and glucose.
CVD ¼ cardiovascular disease; 18F-FDG ¼ 18ﬂuorodeoxyglucose; SUVmax ¼ maximum standardized uptake
value; SUVmean ¼ mean standardized uptake value; TBR ¼ target to background ratio (arterial wall
SUVmax /venous background SUVmean); TBRmax ¼ 90th percentile of the TBR; TBRactive slices ¼ percentage having
at least 1 active slice.
TABLE 3 18F-FDG Uptake Threshold Values
Artery Metric Threshold*
Percentage Above Threshold
Patients at Increased
CVD Risk (%)
Patients With
Known CVD (%)
Carotid SUVmax >1.85 39 66
TBRmax >1.84 52 74
Aorta SUVmax >2.38 43 66
TBRmax >2.68 57 67
*Thresholds were determined using the 90th percentile value observed in the
healthy control subjects.
Abbreviations as in Table 2.
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1202cutoff of TBR $1.60 for the carotids, 48% of the
healthy control subjects had at least 1 active slice
compared with 96% and 100% of the patients at
increased risk for or with known CVD, respectively
(Table 2). The percentage of active slices was 32 
40% in healthy control subjects, 80  31% in patients
at risk for CVD, and 90  19% in known CVD patients
(p ¼ 0.020). The corresponding TBRactive slices values
were also distinct between groups (p ¼ 0.044) (Ta-
ble 2). With cutoffs of $1.80 or $2.00, the number of
healthy control subjects with at least 1 active slice in
the carotids decreased substantially (Online Table 3).
Whereas the %active slices remained signiﬁcantly
different between groups, the TBRactive slices did not
(Online Table 3).
In contrast to the carotids, a much larger propor-
tion of the subjects had active aortic walls. With a
cutoff of $2.40, 88% of the healthy control subjects
had at least 1 active slice; however, the TBRactive slices
and %active slices were not distinct between groups
(Table 2). With the active deﬁnition at $2.60 or $2.80,
more than one-half of the healthy control subjects
still had active segments (Online Table 3). For the
highest cutoff, TBRactive slices was signiﬁcantly
different between groups (p ¼ 0.015).THRESHOLDS. The TBR thresholds based on the
tolerance interval in healthy control subjects are lis-
ted in Table 3. Based on the 90th percentile of this
interval, the threshold for SUVmax was 1.85 for the
carotids and 2.38 for the aorta. For TBRmax, this
threshold was set at 1.84 for the carotids and 2.68 for
the aorta. Figure 2 illustrates both the SUVmax and
TBRmax values per group, with corresponding
thresholds (red dashed lines). For SUVmax, 39% to
43% of those at increased CVD risk versus 66% of the
CVD patients exceeded these thresholds. For TBRmax,
these numbers were in general larger; 52% to 57% of
those at increased CVD risk and 67% to 74% of CVD
patients. In Online Table 4, we also provide the
thresholds using the 95th percentile values.
SAMPLE SIZES. Based on the TBRmax values in the
present study, Figure 3 depicts the sample sizes
required for an estimated drug effect; ranging from
5% to 20%, as has been observed in previous drug trials
(Online Table 1). Carotid TBR as a primary endpoint
requires approximately 20% fewer subjects compared
with aorta TBR. Of note, sample sizes based on SUVmax
values necessitate approximately 20% to 45% more
subjects compared with TBRmax (Online Figure 1).
REPRODUCIBILITY. The intraobserver and interob-
server and interscan agreement within 3 weeks was
excellent for TBRmax as indicated by: 1) ICC values of
>0.95 with narrow 95% conﬁdence intervals; and 2)
the absence of ﬁxed or proportional bias in the Bland-
Altman plots (Online Figure 2). In addition, agree-
ment for all 18F-FDG metrics was also excellent in
healthy control subjects (Online Tables 4 and 5).
DISCUSSION
In the present work, we tested 5 frequently applied
approaches to quantify 18F-FDG uptake in the arte-
rial wall of healthy controls, patients at risk, and
patients with known CVD. Whole artery SUVmax was
signiﬁcantly different between groups, and 18F-FDG
venous blood background values were similar. As
FIGURE 2 Gradual Increase of TBRmax in the Carotids and Aorta Between Groups
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Scatterplots showing the gradual increase in SUVmax and TBRmax for the carotids (A and B) and aorta (C and D) in healthy control subjects,
patients at CVD risk and patients with known CVD. The red dashed line represents the 90th percentile value in healthy control subjects.
CVD ¼ cardiovascular disease; TBRmax ¼ maximum target to background ratio; other abbreviations as in Figure 1.
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1203such, 18F-FDG uptake metrics with background cor-
rections, such as the subtraction or ratio method
(TBR), remained signiﬁcantly different. Moreover,
the TBR and active slice methods accentuated dif-
ferences between the groups. On the basis of these
measures, we determined threshold values for arte-
rial wall inﬂammation and found that >39% of pa-
tients at risk for and >66% with known CVD had
inﬂamed arterial walls, highlighting a potential
therapeutic window for additional anti-inﬂammatory
strategies. Nevertheless, because of the substantial
overlap between healthy controls and patients, the
value of 18F-FDG PET for individual risk assessment
is limited.
18F-FDG UPTAKE METRICS. Here, we assessed the
most commonly reported 18F-FDG endpoints: 1)whole artery SUV; 2) background subtraction; 3)
background ratio (TBR); 4) most-diseased segment;
and 5) active segments. These different approaches
highlight the ability of a single PET scan to measure
multiple aspects of artery’s inﬂammatory status; by
the same token, however, the use of multiple end-
points in drug studies is statistically less robust than a
single readout (31).
As shown in Table 2, differences in background
18F-FDG activity between groups exist but are not
signiﬁcantly different. Both background correction
methods show smaller variations compared with SUV;
in patients with established CVD, the carotid SUV SD
is 0.37 versus 0.28 to 0.30 after background correc-
tion. Consequently, the sample size based on TBR as
readout is smaller than SUV. In addition, in drug
FIGURE 3 Estimated Sample Sizes for Vascular Intervention Studies Based on
Our Results
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Sample sizes required for studies using TBRmax as the primary endpoint. These are
dependent on the estimated drug effect (ranging between 5% and 20%) and target vessel
for imaging (carotid artery or aorta). Abbreviation as in Figure 2.
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1204studies with repeat imaging, the use of a ratio, such as
TBR, limits the effect on signal quantiﬁcation where
variation between scans exists (e.g., weight change,
18F-FDG dose change, 18F-FDG circulation time
change) (36). For these reasons, we favor the use of
TBR, as also endorsed in the recent European Asso-
ciation of Nuclear Medicine position paper on
vascular PET imaging (36).
With respect to the active segment approach, a
substantial bias is induced by eliminating (a poten-
tially large number of) included subjects and imaged
slices (e.g., 48% of healthy subjects included in the
carotid analysis). Consequently, the TBRactive slice
loses much of its power to differentiate between
healthy and diseased subjects. Hence, this approach
should be interpreted with caution, and might be
better suited for changes within 1 individual (20,26).
INFLAMMATION IN DIFFERENT ARTERIAL BEDS. The
validation of 18F-FDG as a marker of plaque inﬂam-
mation originates from histology (5–7) and gene
expression studies (37,38) performed on human ca-
rotid plaque material. Over time, quantiﬁcation of
18F-FDG uptake in the aorta became adopted, sup-
ported by, among others, the histological work in
rabbit models (39,40) and the incremental value in
cardiovascular risk stratiﬁcation (11). The present
study was not designed to investigate the nature of
18F-FDG vascular uptake, but nevertheless showedthat SUVs and TBRs were consistently higher in the
aorta compared with the carotids. This is relevant
when applying an “index vessel approach” to drug
trials because, in w80% of subjects, the index vessel
will originate from the aorta (31). This might be sub-
optimal, as we also demonstrated that aortic TBR as
endpoint requires a larger sample size to detect drug
efﬁcacy (37). Taking into account that the published
drug-induced TBR changes have been relatively small
(ranging between 5% and 15%) (Online Table 1), the
optimal choice of endpoint vessel is important.
The use of the carotid artery as a readout vessel
holds the strongest biological validation linking
the 18F-FDG signal and inﬂammation to recommend it
(5–7,13,37,38). Therefore, we suggest that if the index
vessel approach is not used, the carotid artery is best
validated as primary readout vessel, as highlighted by
Gholami et al. (31).
THRESHOLDS FOR ATHEROSCLEROTIC INFLAMMATION.
Previously, histological carotid plaque studies
demonstrated the correlation between plaque rupture
and inﬂammation (41–43); macrophage-rich areas in
carotid plaques were higher in symptomatic patients
(18  10%) compared with asymptomatic patients (11
4%) (42). Tawakol et al. (6) were the ﬁrst to link plaque
macrophages ex vivo to plaque inﬂammation in vivo,
demonstrating a linear relation between macrophage
content and 18F-FDG uptake in plaques of 17 patients
scheduled for carotid endarterectomy. Carotid plaques
with a macrophage area of <5% had low TBR values,
whereas inﬂamed carotid plaques with macrophage
areas >5% had carotid TBRs between 1.80 and 2.40
(25th and 75th percentiles) (6).
Instead of histology-based approaches, here
we classiﬁed arterial wall inﬂammation using
population-based data by regarding the 90th percen-
tile of 18F-FDG uptake metrics in healthy controls as a
natural threshold. Reassuringly, our healthy control
data are consistent with 18F-FDG uptake values re-
ported in prior studies (22,44–46). In addition, our
carotid uptake values are comparable to those re-
ported in histology- (6,41,42,47) and epidemiology-
based (46) studies, further supporting the validity of
our data.
REPRODUCIBILITY. In line with previous studies
(34,48), we report excellent reproducibility of PET
atherosclerosis imaging in patients at risk and
with known CVD, and extended the ﬁndings into
healthy control subjects. We derived ICCs for interob-
server variability of >0.95, similar to values reported
previously (34,48). Further, we document low inter-
scan TBR changes (<3.5% over a 3-week period),
which is in line with previous placebo-controlled
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: The majority of
patients with CVD have increased inﬂammatory activity in 1 or
more arteries, despite standard-of-care treatments, including
statin use in >80%, reinforcing the potential room for additional
anti-inﬂammatory strategies such as 18F-FDG PET. Arterial FDG
uptake was assessed in healthy control subjects, those with risk
factors, and patients with CVD to derive uptake thresholds in
each subject group as well as the reproducibility of the measures.
TRANSLATIONAL OUTLOOK: Although the measured FDG
metrics were reproducible and signiﬁcantly different between
healthy and diseased subjects, there was signiﬁcant data overlap
between subject categories limiting the generalizability of FDG
PET until substantiated in larger, prospective event-driven
studies.
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1205intervention studies revealing small variations during
a 3- to 6-month timeframe (19,23). Thismakes PET/CT a
highly reproducible and sensitive tool suitable
for identifying patients for anti-inﬂammatory in-
terventions and for determining their effectiveness.
STUDY LIMITATIONS. First, this limited observa-
tional study does not address the predictive value of
arterial PET imaging. Using the present population-
based approach, substantial overlap in 18F-FDG met-
rics between healthy and diseased subjects exists;
therefore, 18F-FDG metrics should be correlated by
outcome data to enable the assessment of “true”
pathological 18F-FDG reference ranges in humans. For
this, the results of larger, long-term prospective
studies (BioImage [32] and Progression and Early
detection of Subclinical Atherosclerosis [33]) are
awaited. Second, despite the published recommen-
dations on PET imaging protocols (34,48), substantial
variation in patient preparation (e.g., glucose levels,
time of fasting), PET image protocol (e.g., time and
areas of scanning) and technology (e.g., acquisition,
reconstruction), and measurement parameters exists
and harmonization is warranted (28–31). As such,
extrapolation of our thresholds is limited to studies
using similar imaging and analysis protocols. Third,
with respect to the population-based approach with a
relative small group size, it must be stressed that
clinical characteristics of the studied groups in this
study (among others, age, sex, lipid levels) should be
taken into account upon extrapolation of our
thresholds. Finally, this study was not designed to
associate 18F-FDG uptake with additional structural or
functional features of the artery because we used a
non–contrast-enhanced CT as part of the PET/CT.
Future studies using magnetic resonance imaging
should improve such assessments as well as correct
for partial volume effects, which is a well-described
limitation of PET imaging (31).
CLINICAL RELEVANCE. For interventional studies,
18F-FDG PET can help to identify subgroups with
inﬂammation above the physiological range and
can provide reproducible measures of drug action. Themajority of patients with known CVD have increased
inﬂammatory activity in 1 or more arteries, despite
standard-of-care treatments, including statin use in
>80%. This residual inﬂammatory activity suggests
the potential for further anti-inﬂammatory strategies
in CVDpatients (49).We await the results of large-scale
studies of such interventions (50,51). Nevertheless,
because of the considerable overlap of 18F-FDG values
between healthy control subjects, those at increased
CVD risk, and patients with known CVD, it is uncertain
whether 18F-FDG PET imaging is capable of identifying
individual patients most likely to beneﬁt from new
therapies.
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